GlaxoSmithKline to promote AB-Biotics Neurofarmagen tests in Brazil
This line of genetic tests helps doctors make a more accurate diagnosis regarding treatment of various psychiatric disorders.
By Biocat
AB-Biotics has reached an agreement with the pharmaceutical multinational corporation GlaxoSmithKline (GSK) to introduce their Neurofarmagen line of genetic tests in Brazil, where there is an estimated market of one million potential patients. As co-founders and CEOs of the Catalan biotechnology firm Miquel Àngel Bonachera and Sergi Audivert confirm "the agreement with GlaxoSmithKline will provide a significant boost for our turnover over the coming years."
The Neurofarmagen genetic tests help doctors identify the best treatment for patients with depression, schizophrenia, bipolar disorder and epilepsy, among other psychiatric disorders, using DNA from a saliva sample.
AB-Biotics currently markets this product in Spain through an agreement signed in October 2012 with pharmaceutical company Almirall. The biotech firm, based in the UAB Research Park and traded on the Alternative Stock Market (MAB) since 2010, is a leader in the development of pharmacogenetic tests for neuropsychiatric disorders, probiotics and other functional ingredients for the food and pharmaceutical industries.
Executives from the company will travel to the top global biotechnology fair, BIO Chicago 2013 in April, with the Catalan delegation of 35 companies coordinated by Biocat. As for GSK, this British company is the fourth multinational in the world in terms of pharmaceutical research.